Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy

Japanese Journal of Clinical Oncology

Volumn 26, Issue 2, 1996, Pages 65-69

  Muro, Kei ^a   Ohtsu, Atsushi ^a   Boku, Narikazu ^a   Chin, Keisho ^a   Oda, Yasushi ^a   Fujii, Takahiro ^a   Hosokawa, Koichi ^a   Yoshida, Shigeaki ^a   Hasebe, Takahiro ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Chemoradiotherapy; Esophageal carcinoma; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; PROTEIN P53;

AGED; ARTICLE; CLINICAL TRIAL; ESOPHAGUS TUMOR; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PROGNOSIS; PROSPECTIVE STUDY; REMISSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030115695     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jjco.a023186     Document Type: Article

References (23)

1. Mcbride OW, Merry D, Givol D: The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83: 130-134, 1986
2. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP: Human p53 localized to short arm of chromosome 17. Nature 319: 783-784, 1986
3. Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13: 1009-1022, 1995
4. Harris AL: Mutant p53: the commonest genetic abnormality in human cancer? J Pathol 162: 5-6, 1990
5. Lane DP: Cancer: a death in the life of p53. Nature 362: 786-787, 1993
6. Hoffman B, Liebermann DA: Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators. Oncogene 9: 1807-1812, 1994
7. Vogelstein B, Kinzier KW: p53 function and dysfunction. Cell 70: 523-526, 1992
8. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991
9. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reinhsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall DH: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845-855, 1992
10. Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109-1114, 1992
11. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4831, 1992
12. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M: Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 70: 293-296, 1994
13. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, Cordon-Cardo C, Cohen AM: p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12: 2043-2050, 1994
14. Ohtsu A, Yoshida S, Boku N, Fujii T, Miyata Y, Hosokawa K, Koba I, Shimizu W, ogino T: Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 25: 261-266, 1995
15. Japanese Society for Esophageal Diseases: Guide Lines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus, 8th ed, Kanehara, Tokyo. 1992
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
17. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991
18. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P: p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63: 317-319, 1991
19. Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, Ikenaga M, Tobe T, Ishizaki K: Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinoma. Cancer Res 53: 846-850, 1993
20. Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, Sugimura H, Kino I: High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 74: 3089-3096, 1994
21. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994
22. 6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer 75: 1339-1342, 1995
23. Seitz JF, Monges G, Perrier H, Giovannini M, Gourvernet J: Absence of surexpression of protein p53 is a powerful and independent predictor of response to treatment of squamous cell esophageal cancer by concurrent radiochemotherapy. Proc Am Soc Clin Oncol 13: 193, 1994